FDA Comments on Skin Stripping Results K.L. Spear MD- Board Certified Dermatologist President Spear Pharmaceuticals- a Generic R/D Company.

Slides:

Advertisements

Similar presentations

Topical Bioequivalence Update Robert Lionberger, Ph.D. Office of Generic Drugs.

Advertisements

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

TESLA Variables Unit: FOSS KIT

Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006.

Skin Care and Science in Harmony Concert has discovered a novel dermatological ingredient, MDI 101, that improves the health of the skin. This discovery.

Methods used to assess and report pain-related endpoints in NDA Ethan Basch, MD, MSc Center for Drug Evaluation and Research.

Skin Stripping vs. Acne Bioequivalent Studies for Tretinoin Generics. Comments at FDA-Advisory Meeting Nov 17, 2000 K.L. Spear M.D. / Dermatologist Spear.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

6/30/2015 Global Trials- Industry Perspective Thomas P. Haverty, MD Group VP Global Clinical Research SPRI.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Transdermal Drug Delivery – Assessment of in vitro skin permeation Shashank Jain.

WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.

Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)

Bioequivalence of Topical Drug Products

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

Scientific Data for Evidence- Based Drug Regulation Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration.

The future prospects for clinical trials in Europe Richard Torbett Chief Economist, EFPIA.

Dermatopharmacokinetics Perspectives from Bioequivalence Viewpoint Historical Development of Dermatopharmacokinetics and Overview of the Guidance Vinod.

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

For Demonstrating Bioequivalence for Generic Topical Dermatologic Drug Products The Pursuit of Alternative Methodologies For Demonstrating Bioequivalence.

Absorption enhancements

Stakeholders In Clinical Research The Pharma Company Professor Phil Warner.

Biomedical Research Objective 2 Biomedical Research Methods.

Generic Topical Dermatologic Drug Products: Issues and Opportunities Jonathan Wilkin, M.D. Director, Division of Dermatologic and Dental Drug Products,

Grobman, K. H. "Confirmation Bias." Teaching about. Developmentalpsychology.org, Web. 16 Sept Sequence Fits the instructor's Rule? Guess.

1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.

20/03/2008 Dept. of Pharmaceutics 1. Use of BIOINFORMATICS in Pharmaciutics 2  Presented By  Shafnan Nazar  Hamid Nasir 

Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.

SYSTEMIC ABSORPTION AS THE MOST ACCURATE AND SENSITIVE METHOD OF DETERMINING BIOEQUIVALENCE OF GENERIC TOPICAL PRODUCTS Chris Hendy Ph.D. Novum Pharmaceutical.

Issues in Generic Substitution: Safety/Efficacy, Cost Savings and Supply Robert J. Herman, MD, FRCPC Professor, Department of Medicine University of Calgary.

Dermatologists By, Faith Moye. Information on Dermatologist To become a Dermatologist you must have 2-4 years in Dermatology. Their specialty is skin,

Welcome and Introduction Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmologic Drug Products ODEV/CDER.

1 Meeting of the Advisory Committee for Reproductive Health Drugs August 29, 2006 Scott Monroe, MD Acting Director, Division of Reproductive and Urologic.

Clinical Data – Dealing with the Chips as they Fall Patricia L. Ruppel, Ph.D. President, dKb Technologies 2003 Spotfire User Conference Boston, 28 October.

Zometa for Patients with Bone Metastases Overview and Review of Study 010 Grant Williams, M.D. Medical Team Leader Division of Oncology Drug Products.

LKPershing Bioequivalence Assessment of three 0.025% tretinoin gel products: Dermatopharmacokinetic vs. Clinical Trial Methods Lynn K. Pershing,

Establishing Efficacy through Randomized Controlled Clinical Trials Ernst R. Berndt, Ph.D. MIT and NBER.

Dermatopharmacokinetics (DPK)

1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.

© Guidant 2005 Surrogate Endpoints and Non-randomized Trials Roseann White Humble Biostatistician.

The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.

What Does it Really Cost to Develop a New Treatment?

Equivalence pharmaceutical equivalents---drugs must have same active ingredients, in same strength, in same dosage form, same RofA. Inactive ingredients.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.

FDA GUIDELINES FOR ADVERTISING COPYWRITERS At the end of this module, you will be able to recall FDA regulations related to pharmaceutical advertising.

Individual Bioequivalence: Have the Opinions of the Scientific Community Changed? Leslie Z. Benet, Ph.D. University of California San Francisco.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Progression of New Drug: From Idea to Public Consumption Chris DeFarlo Writing in the HLTH Professions Unit 2 Prof. Edwards.

March 2008 – DRAFT 1 Electronic Health Record (EHR) Task Force Financial Analysis Isabelle de Zegher and Greg Stadler.

Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.

James P. Simsarian, M.D., MBA Director Multiple Sclerosis Program Neurology Center of Fairfax Ltd.

SOME ISSUES ON THE DETERMINATION OF BIOEQUIVALENCE FOR HIGHLY VARIABLE DRUGS Laszlo Endrenyi University of Toronto Laszlo Tothfalusi Semmelweis University.

Regulation of Generic Animal Drugs in the United States

Source: S. Unchern,  Research is not been completed until the results have been published.  “You don’t write because you want to say something,

Methods to Adjust Doses Based on Exposure-Response Information Points to Consider Richard Lalonde Clinical Pharmacokinetics and Pharmacodynamics Pfizer.

Topic 2: Types of Statistical Studies

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE

Dolianitis C, Kelly J Victorian Melanoma Service,

Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.

Too Early for an Itchy Rash Small Group Teaching Problem Based Learning Department of Dermatology College of Medicine King Saud University Riyadh.

Graphing Techniques.

Henning H. Blume, PhD DSc SocraTec C&S, Oberursel/Germany

Human Gene Therapy Institutional Review Procedures

Gene Array Expression Profiling in Acne Lesions Reveals Marked Upregulation of Genes Involved in Inflammation and Matrix Remodeling Nishit R. Trivedi,

Objective 2 Biomedical Research Methods

Quantitative Assessment of the Transport of Elastic and Rigid Vesicle Components and a Model Drug from these Vesicle Formulations into Human Skin In Vivo

Plasmacytoid Dendritic Cells: A New Cutaneous Dendritic Cell Subset with Distinct Role in Inflammatory Skin Diseases Andreas Wollenberg, Sandra Günther,

Presentation transcript:

FDA Comments on Skin Stripping Results K.L. Spear MD- Board Certified Dermatologist President Spear Pharmaceuticals- a Generic R/D Company

Spear Pharmaceuticals supported the Study of Franz/Lehman u The FDA sponsored skin stripping study of Dr. Pershing was to be a critical step forward in accepting the Draft Guidance for all Dermatological Drugs. u Realizing the importance to Dermatology, Spear Pharma commissioned Dr. Franz and Lehman to perform a similar skin stripping study at another site. u No financial connection between DermTech International and Spear Pharma. Product sent blinded to Franz. u The big issue was: Is this test rugged? Will the two top places in the country, that perform skin stripping, report the same results. u If SS showed consistency we were prepared to start using this test for other drugs in development.

Controversies with Skin Stripping: Location of Test. u Derm products have various sites of action in the skin. u Skin Stripping is really Stratum Corneum stripping. u Antivirals and Antifungals act very superficially. SS theoretically may be the right test. u No available data to confirm that skin stripping predictive of action below the stratum corneum, for example anti-acne drugs and corticosteroids.

Controversies with Skin Stripping: Diseased Skin u No data on the effect of diseased skin. u In Dermatology, we are dealing with diseased skin states like Acne, Psoriasis, or Eczema where the normal stratum corneum is disturbed. u It is a leap of faith to say that how SS behaves on the inner arm of normal skin, predicts the effects of drugs on diseased skin.

Comparing the Two Sites: Technique u For a test to be rugged slight differences in materials or technique should not affect comparative results. u Franz/Lehman followed the draft guidance. u An FDA letter advised that good reproducibility with 4.42 ul/cm 2 amount of drug. u Franz/Lehman adjusted their technique to 5 ul/cm 2 for comparison. Therefore, both sites used a similar amount of drug.

Results of Skin Stripping u Comparing Avita Gel 0.025% to Retin-A 0.025% Gel. u Pershing: Avita 0.025% Gel has a lower AUC and Cmax indicating that it absorbs less into the stratum corneum. u Franz: Avita 0.025% Gel has a higher AUC and Cmax indicating that it absorbs more into the stratum corneum.

Conclusion on Skin Stripping: For tretinoins u If the two top DPK research sites in the country get contradictory results, the SS methodology is not adequately developed. u The Draft guidance seeks to apply this skin stripping test to all Dermatological drugs. u We can not comment on other classes of Derm drugs, but in this example for Anti-Acne tretinoins, SS is not rugged.

Clinical Trials vs. Surrogate Markers u Draft guidance says: Comparative clinical trials are difficult to perform, highly variable, and insensitive. u Spear Pharma has performed four: 400 patient clinical trials on tretinoin products, showing Bioequivalence to brand. u Skin stripping study discussed today is certainly as difficult to perform, and it seems as highly variable and insensitive. u Some claim that the Draft Guidance must be accepted because Generics can not be approved in any other way. Clinical trials can be done, and remain the only confirmatory studies for drugs that act below the stratum corneum.

Conclusion on Skin Stripping u The FDA seeks to lump all Dermatologic Drugs into one test. The skin is complex and has multiple sites of action, we believe one test does not fit all. u We suggest the SS Draft Guidance be amended to include only Stratum Corneum drugs. u Other DPK tests should be investigated for the deeper action Derm drugs like the Cadaver skin test.

Avita Clinical correlation to SS u How does Avita penetrate into Stratum Corneum? u Avita promoted as less irritating. u J.Pharm. Sci Oct;86(10); Quigley et al. of Penederm.: Avita with the PP-2 compound reduces tretinoin penetration while enhancing epidermal deposition compared to Retin-A. u Therefore, skin stripping of stratum corneum should have more Avita gel with a higher AUC, (Area under the curve) consistent with Franz’s results. u Clinical results: Lucky et al. J.A.A.D. in 215 patient study no difference clinically in total lesion counts at 12 weeks for Avita 0.025% Gel vs Retin-A 0.025% gel.